

A pregnancy exposure registry study to assess clinical follow-up and outcomes of pregnancies exposed to ulipristal acetate 30 mg

First published: 24/02/2020

Last updated: 05/11/2024

Study

Ongoing

Administrative details

EU PAS number

EUPAS33796


Study ID

49109

DARWIN EU® study

No

Study countries

 Austria

 Czechia

 Finland

-  France
 -  Germany
 -  Greece
 -  Ireland
 -  Italy
 -  Liechtenstein
 -  Malta
 -  Netherlands
 -  Norway
 -  Poland
 -  Portugal
 -  Romania
 -  Spain
 -  Switzerland
 -  United Kingdom
-

Study status

Ongoing

Contact details

Study institution contact

Arna Hrund Arnardóttir arnahrundarnardottir@dada.nl

Study contact

arnahrundarnardottir@dada.nl

Primary lead investigator

Arna Hrund Arnardóttir

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 27/03/2020

Actual: 19/05/2020

Study start date

Planned: 22/05/2020

Actual: 22/05/2020

Date of final study report

Planned: 21/12/2027

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Aristo Pharma GmbH, Aspen Healthcare Malta Limited, BIOGARAN, ELPEN Pharmaceutical Co. Inc, Eugia Pharma (Malta) Ltd., Exeltis Pharmaceuticals Holding, S.L., Farmitalia s.r.l, HELM AG, Mylan, Hexal AG, STADA Arzneimittel AG, Zentiva Group, a.s.

Study protocol

[230530-Ulipristal-PASS-Protocol-v4.0_Redacted.pdf](#) (2.5 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Data collection methods:

Primary data collection

Main study objective:

The primary objective of this pregnancy registry is to collect all data about pregnancy and pregnancy outcome in women exposed to ulipristal acetate 30mg for any reason, e.g. unrecognized pregnancy before intake or product

failure.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Post-marketing, non-interventional, web-based joint pregnancy registry.

Retrospective collection of pregnancy data and pregnancy outcomes.

Study drug and medical condition

Medicinal product name

ULIPRISTAL ACETATE

Study drug International non-proprietary name (INN) or common name

ULIPRISTAL ACETATE

Anatomical Therapeutic Chemical (ATC) code

(G03AD02) ulipristal

ulipristal

Population studied

Age groups

- Adolescents (12 to < 18 years)

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
-

Estimated number of subjects

25

Study design details

Data analysis plan

Descriptive statistics will be the primary approach for summarizing data from the pregnancy exposure registry. Data will be presented for all subjects enrolled in the registry. No stratified analysis is foreseen or has been planned for this study.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Exposure registry

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No